Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial Meeting Abstract
| Authors: | Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; Segar, J. M.; Wei, M.; Liu, J.; Spira, A. I.; McGuinness, J. E.; Ahnert, J. R.; Ma, C. X.; Sirvén, M. B.; Curigliano, G.; Varkaris, A. |
| Abstract Title: | Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Start Page: | 1086 |
| Language: | English |
| ACCESSION: | WOS:001509228900001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.1086 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
